European Patent Office

T 0832/18 (Method for determining responsiveness of cancer to treatments targeting EGFR/GENERAL HOSPITAL CORPORATION & DANA-FARBER CANCER INSTITUTE) of 09.12.2024

European Case Law Identifier
ECLI:EP:BA:2024:T083218.20241209
Date of decision
9 December 2024
Case number
T 0832/18
Online on
30 October 2025
Petition for review of
-
Application number
05757467.5
Language of proceedings
English
Distribution
No distribution (D)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
METHOD TO DETERMINE RESPONSIVENESS OF CANCER TO EPIDERMAL GROWTH FACTOR RECEPTOR TARGETING TREATMENTS
Applicant name
THE GENERAL HOSPITAL CORPORATION
Dana-Farber Cancer Institute, Inc.
Opponent name
James Poole Limited
Strawman Limited
Board
3.3.08
Headnote
-
Relevant legal provisions
European Patent Convention Art 83
Keywords
Main request and first to third auxiliary requests and P0 to P3 - sufficiency of disclosure (no)
Catchword
-
Cited cases
-
Citing cases
-

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.